A- A A+

Kanada. Release of First-Ever National Clinical Guidelines on Substance Use Disorders among Older Canadians!

Toronto, Ontario – Canadian healthcare providers now have the tools they need to better support the prevention, assessment and treatment of older adults at risk of, or living with, substance use disorders. The Canadian Coalition for Seniors’ Mental Health (CCSMH) officially launched 4 sets of Clinical Guidelines on Substance Use Disorders in Older Adults today. (Canadian Coalition for Seniors' Mental Health, 20.01.2020)


Canadian Guidelines on Opioid Use Disorder Among Older Adults. 

Canadian Coalition for Seniors’ Mental Health, Toronto, Canada (2019)

According to the World Health Organization, people over the age of 50 accounted for 39% of deaths from drug use disorders in 2015. Of those deaths in older adults (age ≥ 65), approximately 75% were linked to the use of opioids (Degenhardt & Hall, 2012; UNODC, 2018). 

In Canada, 43.9% of adults > 55 years of age have used a prescription opioid and 1.1% of that group have done so daily (or almost daily) in the last year (Canadian Centre on Substance Use and Addiction, 2018).

There is a growing population of older adults developing opioid use disorder (OUD). In addition to this, there are older adults with longstanding OUD (including people who use illicit opioids) that require treatment for their addiction and related health problems.


Opioid-Agonisten-Therapien - Leitprinzipien für Gesetzgebung und Reglementierung

Expertengruppe bezüglich gesetzlicher Rahmenbedingungen für die Behandlung des Opioidabhängigkeitssyndroms durch Verschreibung von Opioid-Agonisten-Arzneimittel

Pompidou Group/Groupe Pompidou, Council of Europe/Conseil de Europe, 2019


Opioid agonist treatment - Guiding principles for legislation and regulations

Expert group on the regulatory framework for the treatment of opioid dependence syndrome and the prescription of opioid agonist medicines.

Pompidou Group/Groupe Pompidou, Council of Europe/Conseil de Europe, 2019


International Standards for the Treatment of Drug Use Disorders



Hepatitis C Guidance 2019 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection.

Ghany MG, Marks KM, Morgan TR, Wyles DL, Aronsohn AI, Bhattacharya D, Broder T, Falade-Nwulia OO, Feld JJ, Gordon SC, Heller T, Jhaveri RR, Jonas MM, Kiser JJ, Linas BP, Lo Re V, Peters MG, Reddy KR, Reynolds A, Scott JD, Searson G, Spradling P, Terrault NA, Trooskin SB, Verna EC, Wong JB, Woolley AE, Workowski KA.

Hepatology. 2019 Dec 9. doi: 10.1002/hep.31060. 


USA. Recovery Housing: Best practices and suggested guidelines.

(…) The SUPPORT legislation seeks to improve resident care for individuals suffering from a substance use disorder who are in need of supportive recovery-oriented transitional housing. The Administration has dedicated time, attention, and resources to ensuring that individuals with substance use disorders have access to lifesaving medications, treatments, and services in settings throughout the continuum of care, including recovery housing. This document is intended to serve as a guidance tool for states, governing bodies, treatment providers, recovery house operators, and other interested stakeholders to improve the health of their citizens related to substance use issues. This report identifies ten specific areas, or guiding principles, that will assist states and federal policy makers in defining and understanding what comprises safe, effective, and legal recovery housing. (SAMHSA - Substance Abuse and Mental Health Services Administration, USA, OKTOBER 2019)


Update: Interim Guidance for Health Care Providers Evaluating and Caring for Patients with Suspected E-cigarette, or Vaping, Product Use Associated Lung Injury — United States, October 2019.

Siegel DA, Jatlaoui TC, Koumans EH, et al. 

MMWR Morb Mortal Wkly Rep. ePub: 11 October 2019. doi.org/10.15585/mmwr.mm6841e3


Kanada. Injectable opioid agonist treatment for opioid use disorder: a national clinical guideline

Nadia Fairbairn, Josey Ross, Michael Trew, Karine Meador, Jeff Turnbull, Scott MacDonald, Eugenia Oviedo-Joekes, Bernard Le Foll, Marie-Ève Goyer, Michel Perreault and Christy Sutherland

CMAJ September 23, 2019 191 (38) E1049-E1056; doi.org/10.1503/cmaj.190344 


Kanada. CRISM National Injectable Opioid Agonist Treatment Guideline

CRISM developed the first national injectable opioid agonist treatment (iOAT) guideline in the world. This guideline includes two companion documents: a clinical guideline and an operational guidance document.


Schweiz. Opioid-Agonisten-Therapien - Leitprinzipien für Gesetzgebung und Reglementierung

Expertengruppe bezüglich gesetzlicher Rahmenbedingungen für die Behandlung des Opioidabhängigkeitssyndroms durch Verschreibung von Opioid-Agonisten-Arzneimittel. (Pompidou Group – Groupe Pompidou, Deutsche Ausgabe: März 2019)


Kanada. CRISM National Guideline for the Clinical Management of Opioid Use Disorder / Lignes Directrices Nationales de L’Initiative Canadienne de Recherche sur L’Abus de Substances Du Trouble Li é à L’usage D’opioïdes, 2018


Working with people who use drugs - Guidance for homelessness accommodation services

There is no legal requirement for homelessness services to provide specific support to individuals who use drugs, although it is common for people experiencing homelessness to be using drugs. Homelessness services vary in their tolerance to drug use, and the use of drugs can cause challenges for clients who are expected to adhere to organisational policies and procedures. This can be equally challenging for the organisation. There is, however, an opportunity for homelessness services to work with people using drugs, in order to help reduce harm, improve future prospects and increase opportunities of re-integration in to wider society. (homeless link, UK, Mai 2019)


Schweiz. Hepatitis C bei Drogenkonsumierenden: Richtlinien mit settingspezifischen Factsheets.

Bundesamt für Gesundheit, Infodrog. Bern: Bundesamt für Gesundheit, 2019.


Evidence-Based Guidelines for EMS Administration of Naloxone.

Williams K, Lang ES, Panchal A, Gasper JJ, Taillac P, Gouda J, Hedges M.

Prehosp Emerg Care. 2019 Mar 29:1-41. doi: 10.1080/10903127.2019.1597955. 


Methadone Safety: A Clinical Practice Guideline From the American Pain Society and College on Problems of Drug Dependence, in Collaboration With the Heart Rhythm Society

Chou, Roger et al.

The Journal of Pain , Volume 15 , Issue 4 , 321 - 337 


EACS-HIV-LEITLINIEN - Version 9.1 - Oktober 2018 – Englisch

EACS produces the European Guidelines for treatment of HIV-positive adults in Europe. The English version is regularly updated by the guideline panels. A major update is published once per year in autumn and translated into additional languages. (European AIDS Clinical Society / EACS)


HIV. Neue EACS Leitlinien 

Die Europäische Aids-Gesellschaft hat im Oktober die Leitlinien aktualisiert. Dabei folgt sie mehr denn je internationalen Trends. Hier die wichtigsten Neuerungen.(Die deutsche Übersetzung liegt noch nicht vor, Anm. Forum Substitutionspraxis) (hiv&more, Ausgabe 4/2018)


EMCDDA/CCSA. Cannabis und Führen eines Kraftfahrzeugs: Fragen und Antworten für das Finden einer politischen Entscheidung

Europäische Beobachtungsstelle für Drogen und Drogensucht und Canadian Centre on Substance Use and Addiction (2018), Amt für Veröffentlichungen der Europäischen Union, Luxemburg


PEP – Leitlinien Update 2018: Deutsch-Österreichische Leitlinien zur HIV-Postexpositionsprophylaxe

Die wichtigste Änderung betrifft die empfohlenen Medikamente zur PEP. (Zusammenfassung in: hiv&more, Ausgabe 3/2018)


Charité. Mustercurriculum Patientensicherheit der Weltgesundheitsorganisation. Multiprofessionelle Ausgabe. 

Charité – Universitätsmedizin Berlin (Hg.) (2018): Berlin: Charité – Universitätsmedizin Berlin, ISBN: 978-3-00-060626-7


WHO legt Leitlinie zur somatischen Versorgung psychisch Kranker vor

Genf – Menschen mit schweren psychischen Störungen – mittelschwere bis schwere Depressionen, bipolare Störungen, Schizophrenie und andere psychotische Störungen – haben in der Regel eine Lebenserwartung, die zehn bis 20 Jahre kürzer ist als die der allgemeinen Bevölkerung. Darauf weist die Weltgesundheitsorganisation WHO hin. Die Mehrheit dieser vorzeitigen Todesfälle sei auf somatische Erkrankungen zurückzuführen. (aerzteblatt.de, 09.11.2018)


WHO Guidelines. Management of physical health conditions in adults with severe mental disorders

World Health Organization, Publication date: 2018, Languages: English, ISBN: 978-92-4-155038-3


EMCDDA. Best Practice Portal (Deutsch)

Das Best Practice Portal (Portal für vorbildliche Verfahren) soll Ihnen bei der Suche nach praktischen und verlässlichen Informationen über erfolgreiche (und wirkungslose) Maßnahmen in den Bereichen Prävention, Behandlung, Schadensminimierung und soziale Wiedereingliederung helfen. Hier können Sie schnell bewährte Interventionen ermitteln, Ihre Ressourcen effektiv planen und Ihre Maßnahmen durch die Anwendung von Tools, Standards und Leitlinien verbessern. (EMCDDA, Lissabon, Oktober 2018)


Opioid agonist treatment Guiding principles for legislation and regulations (Pompidou Group)

Expert group on the regulatory framework for the treatment of opioid dependence syndrome and the prescription of opioid agonist medicines. (Pompidou Group/Counsil of Europe, Co-operation Group to Combat Drug Abuse and Illicit Trafficking in Drugs, 2018, engl./frz.)


As the NAS Crisis Worsens, a New Study Offers Treatment Guidelines

The incidence of neonatal abstinence syndrome (NAS) has been climbing steadily, according to a 2016 Morbidity and Mortality Weekly Report from the Centers for Disease Control and Prevention (CDC). The report, published August 12, indicated that the number of NAS cases rose from 1.5 per 1,000 hospital births in 1999 to 6 per 1,000 in 2013.

Yet guidelines for treating NAS have been lacking, according to a study in JAMA Pediatrics. The study, published online June 18, found that although several different approaches are being used, “no universal evidence-based pharmacological treatment strategy exists.” The article also noted that the FDA hasn’t approved any drug for treating infants who have NAS.

The authors of the JAMA Pediatrics study said that, without clear treatment guidelines, caregivers have typically chosen either methadone or morphine to treat their young NAS patients.

New Guidelines

Which medication—methadone or morphine—is better, and how to decide on an appropriate dose? Some studies have suggested basing the dose on the infant’s weight; others, on the severity of NAS, as assessed by the Finnegan Neonatal Abstinence Scoring System.

The JAMA Pediatrics team set out to answer the medication questions. They designed a treatment plan, then carried out what they believe is the first multisite, double-blind, randomized trial comparing the safety and efficacy of methadone and morphine in NAS. They published their results online June 18. (atforum.com, USA, 04.09.2018)


Deutsch-Österreichische Leitlinien zur antiretroviralen Therapie der HIV-Infektion (Version 7 vom 29.11.2017)

Deutsche AIDS-Gesellschaft, Österreichische AIDS-Gesellschaft


USA. Johns Hopkins experts create opioid prescribing guidelines for 20 common surgical procedures

A Johns Hopkins expert panel of health care providers and patients have announced what is, to their knowledge, the nation's first set of operation-specific opioid prescribing guidelines. The guidelines are based on the premise that opioid prescribing limits should be based on the operation performed rather than a blanket approach. The ranges offered for each of 20 common operations generally call for reductions from the current rates of opioid prescription, and the researchers say that patients themselves favor using less of the drugs than physicians often prescribe. (Johns Hopkins University School of Medicine, USA, 14.08.2018)